Aileron Therapeutics Acquires Lung Therapeutics
Aileron Therapeutics, Inc. has announced its acquisition of Lung Therapeutics. Financial terms of the deal were not disclosed. Lung Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for underserved, life-threatening lung conditions. The Lung Therapeutics pipeline features leading programs LTI-01 and LTI-03, two candidates that indicate a novel way to treat lung diseases. Aileron Therapeutics is a chemoprotection oncology company focused on the clinical development of its lead product candidate, ALRN-6924, to protect cancer patients against chemotherapy-induced toxicities. Following the acquisition, Aileron entered into a definitive... Read More »
Roche Acquires Telavant for $7.1 Billion
Roche Holding AG announced on October 23 that it will acquire Telavant Holdings from its majority owner, Roivant Sciences. Under the terms of the agreement, Roche will pay a purchase price of $7.1 billion upfront and a near-term milestone payment of $150 million. Telavant is a biotechnology company that produces drugs to treat inflammatory and fibrotic diseases. It is in the process of developing a new therapy for patients with Crohn’s disease. Telavant was jointly formed by Roivant and Pfizer, Inc. in 2022 to develop and commercialize RVT-3101, a monthly subcutaneously administered anti-TL1A antibody, in the United States and Japan. Roivant currently owns 75% of the issued and... Read More »
Eli Lilly Acquires POINT Biopharma Global For $1.4 Billion
Eli Lilly and Company announced on October 2 that it acquired POINT Biopharma Global, Inc. for approximately $1.4 billion. Lilly will commence a tender offer to acquire all outstanding shares of POINT for a purchase price of $12.50 per share in cash payable at closing. The price represents a premium of approximately 87% to POINT’s closing stock price on Oct. 2, 2023, the last trading day before the announcement of the transaction was made, and 68% to the 30-day volume-weighted average price. POINT Biopharma Global is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight... Read More »
SOHM Acquires ABBIE
On September 25, SOHM, Inc. announced that it acquired ABBIE from CGA 369 for $10 million. ABBIE is a gene-editing platform which can deliver genetic payloads using non-viral vectors. ABBIE uses targeted integration to insert larger DNA sequences, including full genes, into a desired loci of the target cell’s genome. ABBIE will be able to edit genes of a large number of cell types at different stages of their life cycles, overcoming the limitations of current cell editing and cell engineering technologies. SOHM, is a generic pharmaceutical manufacturing and marketing company with a vision of “Globalè Prospèro” that tries to build continuous growth. SOHM’s... Read More »
Berkeley Biologics Acquires Elutia’s Orthobiologics Business Unit
Elutia Inc. (previously known as Aziyo Biologics, Inc.) announced on September 18 that it divested its Orthobiologics business unit to Berkeley Biologics LLC. Mizuho Securities USA LLC acted as advisor to Elutia. According to data captured in the LevinPro HC database, this transaction marks the 110th Biotechnology transaction of the year. Elutia will receive cash proceeds of up to $35 million, comprising an upfront payment at closing of $15 million plus potential earnout payments of up to $20 million over a five-year period. The transaction is expected to close in the fourth quarter of 2023. Orthobiologics are therapies that can be used by orthopaedic... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
